Eurofins Executive and Leadership Team

Alexandra Kim, the Chief Financial Officer, Business Line at Eurofins, directs financial strategy and performance across diverse business units. Kim oversees fiscal operations, ensuring robust financial health and strategic resource allocation for Eurofins' extensive analytical testing services. This leadership position involves managing budgets, forecasting, and financial reporting to support growth in areas like food, environmental, and pharmaceutical product testing. Alexandra Kim's financial acumen is critical for the company's prominent standing in discovery pharmacology, forensics, and advanced material sciences. The Chief Financial Officer, Business Line also guides financial planning for agroscience contract research and BioPharma contract development and manufacturing, reinforcing Eurofins' market leadership. Kim's responsibilities include optimizing financial performance in genomics and supporting clinical studies, as well as driving profitability in the expanding field of esoteric and molecular clinical diagnostic testing.

Neil Dominy, the Chief Operating Officer at Eurofins, directs the operational execution across the company's extensive global network. Overseeing the day-to-day functions, Dominy ensures the efficient delivery of a comprehensive range of analytical testing services. This leadership role involves optimizing laboratory operations and streamlining processes to support clients in food, environmental, pharmaceutical, and cosmetic product testing. By driving operational excellence, Neil Dominy directly impacts the company's ability to maintain its world-leading position in discovery pharmacology, forensics, and advanced material sciences. The Chief Operating Officer's focus extends to enhancing the efficiency of agroscience contract research services and supporting the rapid growth in BioPharma contract development and manufacturing. Dominy's strategic oversight ensures seamless integration of new acquisitions and the scaling of services to meet evolving market demands, particularly in the burgeoning field of esoteric and molecular clinical diagnostic testing.

Cathy Poye, the President, Eurofins J3 Resources, Inc at Eurofins, leads the strategic direction and operational management of this specialized division. Poye drives the expansion of J3 Resources' service offerings, focusing on delivering high-quality analytical testing solutions. This executive role involves overseeing client relationships and ensuring the efficient execution of projects within the food, environmental, and pharmaceutical sectors. Cathy Poye's leadership is instrumental in maintaining Eurofins' reputation for excellence in discovery pharmacology and advanced material sciences. The President, Eurofins J3 Resources, Inc also guides the division's contribution to agroscience contract research and BioPharma contract development. Poye's focus on operational efficiency and client satisfaction directly supports Eurofins' broader mission in genomics and clinical diagnostics, reinforcing the company's global market presence.

Jason Neat, the President, Eurofins Bioanalytical & Viracor-Biopharma Services at Eurofins, spearheads the strategic growth and operational excellence of these critical service lines. Neat directs the expansion of bioanalytical testing and biopharma services, ensuring compliance with rigorous industry standards. This leadership role involves optimizing laboratory operations and fostering innovation to support clients in pharmaceutical development and clinical studies. Jason Neat's focus on scientific integrity and client collaboration is key to Eurofins' prominent position in BioPharma contract development and manufacturing. The President, Eurofins Bioanalytical & Viracor-Biopharma Services also oversees the integration of advanced diagnostic capabilities, contributing to Eurofins' emerging strength in esoteric and molecular clinical diagnostic testing. Neat's strategic oversight ensures these divisions consistently deliver high-value solutions to the biopharmaceutical industry.

Jp Boutrand, the President at Eurofins, directs strategic initiatives and operational oversight for key business segments. Boutrand drives the expansion of Eurofins' comprehensive analytical testing services, ensuring alignment with the company's global leadership objectives. This executive role involves fostering cross-functional collaboration and optimizing resource allocation to enhance service delivery across various industries. Jp Boutrand's leadership is crucial for maintaining Eurofins' strong presence in food, environmental, and pharmaceutical product testing. The President's focus extends to advancing capabilities in discovery pharmacology, forensics, and advanced material sciences. Boutrand's strategic guidance supports the company's growth in agroscience contract research and BioPharma contract development, reinforcing Eurofins' commitment to scientific innovation and market leadership.

Camila Gadotti, the President at Eurofins, leads strategic development and operational execution for designated business units. Gadotti drives the enhancement of Eurofins' extensive portfolio of analytical testing services, ensuring superior client outcomes. This leadership position involves overseeing market expansion and optimizing service delivery in critical sectors such as food, environmental, and cosmetic product testing. Camila Gadotti's strategic vision supports Eurofins' world-leading position in discovery pharmacology and advanced material sciences. The President's responsibilities include guiding innovation in agroscience contract research and BioPharma contract development and manufacturing. Gadotti's focus on operational efficiency and scientific rigor directly contributes to Eurofins' growing influence in esoteric and molecular clinical diagnostic testing.

Lenore Coyle, the President, Eurofins CRL Cosmetics, Inc. at Eurofins, directs the strategic vision and operational management of the cosmetics testing division. Coyle drives the expansion of specialized analytical services tailored for the cosmetic industry, ensuring adherence to stringent quality and regulatory standards. This executive role involves overseeing client partnerships and optimizing laboratory processes to deliver precise testing results. Lenore Coyle's leadership is key to Eurofins' prominent position in cosmetic product testing and advanced material sciences. The President, Eurofins CRL Cosmetics, Inc. also contributes to the company's broader capabilities in discovery pharmacology and BioPharma contract development. Coyle's focus on innovation and client satisfaction reinforces Eurofins' commitment to scientific excellence across its diverse service offerings.

Cheryl Stephenson, the President at Eurofins, leads strategic initiatives and operational oversight for key business segments. Stephenson drives the enhancement of Eurofins' comprehensive analytical testing services, ensuring alignment with the company's global leadership objectives. This executive role involves fostering cross-functional collaboration and optimizing resource allocation to enhance service delivery across various industries. Cheryl Stephenson's leadership is crucial for maintaining Eurofins' strong presence in food, environmental, and pharmaceutical product testing. The President's focus extends to advancing capabilities in discovery pharmacology, forensics, and advanced material sciences. Stephenson's strategic guidance supports the company's growth in agroscience contract research and BioPharma contract development, reinforcing Eurofins' commitment to scientific innovation and market leadership.

Mary Krogull, the President at Eurofins, directs strategic development and operational execution for designated business units. Krogull drives the enhancement of Eurofins' extensive portfolio of analytical testing services, ensuring superior client outcomes. This leadership position involves overseeing market expansion and optimizing service delivery in critical sectors such as food, environmental, and cosmetic product testing. Mary Krogull's strategic vision supports Eurofins' world-leading position in discovery pharmacology and advanced material sciences. The President's responsibilities include guiding innovation in agroscience contract research and BioPharma contract development and manufacturing. Krogull's focus on operational efficiency and scientific rigor directly contributes to Eurofins' growing influence in esoteric and molecular clinical diagnostic testing.

Scott Fyfe, the Chief Technology Officer at Eurofins, architects the technological infrastructure supporting the organization's vast analytical capabilities. Fyfe drives innovation in digital solutions and laboratory information management systems, crucial for maintaining Eurofins' leadership in food, environmental, and pharmaceutical testing. The Chief Technology Officer oversees the development and implementation of advanced technologies that enhance the precision and speed of discovery pharmacology, forensics, and material sciences testing. Scott Fyfe's strategic vision guides the integration of cutting-edge platforms for agroscience contract research and BioPharma contract development. This role is pivotal in advancing Eurofins' prominent position in genomics and supporting clinical studies through robust data management and analysis. Fyfe ensures that technological advancements directly contribute to the company's emerging strength in esoteric and molecular clinical diagnostic testing, reinforcing Eurofins' commitment to scientific progress and client service.